psalexa
logo

Hyperhidrosis Therapeutics Pipeline Analysis, 2017

Hyperhidrosis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS11317
Available Format:
Pages: 55

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Hyperhidrosis is a medical condition in which the eccrine glands are overactive and produce more sweat than normal to regulate normal body temperature. There are two types of hyperhidrosis namely primary focal hyperhidrosis and secondary (generalized) hyperhidrosis. Primary focal hyperhidrosis generally occurs at multiple locations on the body including axillary, palmar, plantar, trunk/inguinal, craniofacial and it often begins in childhood or adolescence age. Secondary (generalized) hyperhidrosis occur due to excessive sweating caused by medical conditions such as menopause, diabetes, obesity and side effect of medications such as anti-depressants. Hyperhidrosis patients worry about over-sweating causing often other emotional problems including depression, social isolation, and decreased confidence. Atacama Therapeutics, Inc. is in the process of developing TC-5214 in phase II for the treatment of hyperhidrosis.

 

HYPERHIDROSIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
Hyperhidrosis Therapeutics Pipeline Analysis
 

Pipeline Analysis

As of November 2017, the hyperhidrosis therapeutics pipeline comprises 12 drug candidates in different stages of development, with maximum number of active drugs in the Phase II of development.

Competitive Landscape

Some of the players developing drugs for the treatment of hyperhidrosis include Dermira, Inc., Allergan, Plc, TheraVida Inc., Atacama Therapeutics, Inc. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry